Blood storage composition and blood collection container
The blood preservation composition with an anticoagulant, disaccharide, and polyether compound stabilizes blood cells, preventing DNA contamination and maintaining plasma volume, thus ensuring reliable cfDNA tests.
Patent Information
- Application Number
- JP2024513115
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-09-29
- Filing Date
- 2023-09-01
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-09-01
AI Technical Summary
Existing blood collection containers with conventional anticoagulants face issues such as contamination of genomic DNA from blood cells into the plasma layer and a decrease in plasma volume during storage, which affects the reliability and accuracy of cfDNA tests.
A blood preservation composition comprising an anticoagulant, a disaccharide or polysaccharide, and a polyether compound like polyethylene glycol, which stabilizes blood cells and prevents DNA leakage and plasma volume reduction by protecting cell membranes and preventing water absorption.
The composition effectively suppresses blood cell-derived DNA contamination in the plasma layer and maintains or increases plasma volume after storage, ensuring reliable cfDNA testing results.
Smart Images

Figure 0007586593000004 
Figure 0007586593000001 
Figure 0007586593000002
Abstract
Description
[Technical field]
[0001] The present invention relates to a blood storage composition which is mixed with blood for use. The present invention also relates to a blood collection container which uses the blood storage composition. [Background technology]
[0002] Blood contains free DNA (cell free DNA, cfDNA). It is known that cfDNA is present at higher concentrations in the bodily fluids of people with malignant tumors and infectious diseases compared to healthy people. In recent years, tests using cfDNA as a sample have been conducted in the fields of cancer and genetic diseases. Tests using cfDNA as a sample place a smaller burden on patients than tests using diseased tissue collected from patients.
[0003] Clinical testing generally involves the following steps (1) to (3): (1) Blood is collected in a blood collection container that contains a composition that includes an anticoagulant. (2) The blood is separated into a blood cell layer and a plasma layer by centrifuging the blood collection container in which the blood has been collected, or the like. (3) The plasma is collected, and a test is performed using the cfDNA contained in the plasma as a sample.
[0004] The following Patent Document 1 describes a method for stably collecting cfDNA using a blood collection device in which a composition containing EDTA, a specific urea, and glycine is contained in a container.
[0005] The following Patent Document 2 describes a method for preserving cfDNA using a blood collection tube in which a composition containing polyethylene glycol (PEG), EDTA, etc. is contained. Patent Document 2 describes that the composition stabilizes blood, thereby suppressing the contamination of plasma with genomic DNA. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] WO2013 / 123030A2 [Patent Document 2] WO2017 / 201612A1 Summary of the Invention [Problem to be solved by the invention]
[0007] In clinical practice, a certain amount of time may pass before a blood sample taken from a patient is subjected to testing. For example, when the sample is transported to a testing facility or when there are a large number of samples waiting to be tested at the testing facility, several days may pass between the time the blood sample is taken and the time the sample is subjected to testing. Therefore, in clinical practice, the blood may be stored in a blood collection container for several days in a state where the composition containing an anticoagulant is mixed with the blood, or the blood may be stored for several days after the blood cell layer and the plasma layer are separated.
[0008] In blood collection containers containing conventional compositions containing anticoagulants, blood cells may be destroyed or killed during storage, causing genomic DNA (gDNA) to leak out of the blood cells, such as white blood cells, and the blood cell-derived DNA may become mixed into the plasma layer. In tests using cfDNA as a sample, the test results are likely to fluctuate if a relatively large amount of blood cell-derived DNA is mixed into the plasma layer.
[0009] Furthermore, in blood collection containers containing conventional compositions containing anticoagulants, the amount of plasma after storage may decrease compared to the amount of plasma before storage because the water in the plasma is gradually absorbed by blood cells, which may make it impossible to secure the amount of plasma required for testing or retesting.
[0010] The object of the present invention is to provide a blood storage composition that can suppress the incorporation of DNA derived from blood cells into the plasma layer and can suppress the decrease in the amount of plasma after storage compared to the amount of plasma before storage. Another object of the present invention is to provide a blood collection container using the above blood storage composition. [Means for solving the problem]
[0011] In a broad aspect of the present invention, there is provided a blood storage composition comprising an anticoagulant (A), a compound (B) which is a disaccharide, a disaccharide derivative, a polysaccharide or a polysaccharide derivative, and a polyether compound (C) which is a polyethylene oxide or a polyethylene glycol.
[0012] In a specific aspect of the blood storage composition of the present invention, the compound (B) includes a disaccharide and a polysaccharide or a derivative of a polysaccharide.
[0013] In a specific aspect of the blood storage composition of the present invention, the compound (B) includes trehalose or sucrose, and dextran or hydroxyethyl starch.
[0014] In a specific aspect of the blood storage composition according to the present invention, the polyether compound (C) contains polyethylene glycol.
[0015] In a specific aspect of the blood storage composition according to the present invention, the blood storage composition contains an apoptosis inhibitor (D).
[0016] In a specific aspect of the blood storage composition of the present invention, the apoptosis inhibitor (D) comprises Q-VD-OPH, Z-DEVD-FMK, or Z-VAD-FMK.
[0017] In a specific aspect of the blood storage composition according to the present invention, the blood storage composition contains an inorganic salt (E).
[0018] In a specific aspect of the blood storage composition according to the present invention, the blood storage composition contains water.
[0019] In a broad aspect of the present invention, there is provided a blood collection container comprising a blood collection container body and a blood storage composition contained within the blood collection container body, the blood storage composition being the blood storage composition described above.
[0020] In a specific aspect of the blood collection container according to the present invention, a plasma separation material is not contained within the blood collection container body. Effect of the Invention
[0021] The blood storage composition of the present invention comprises an anticoagulant (A), a compound (B) which is a disaccharide, a disaccharide derivative, a polysaccharide or a polysaccharide derivative, and a polyether compound (C) which is polyethylene oxide or polyethylene glycol. Since the blood storage composition of the present invention has the above-mentioned configuration, it is possible to suppress the incorporation of DNA derived from blood cells into the plasma layer, and also to suppress the reduction in the plasma volume after storage compared to the plasma volume before storage. [Brief description of the drawings]
[0022] [Figure 1] FIG. 1 is a front cross-sectional view that shows a schematic diagram of a blood collection container according to one embodiment of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0023] The present invention will be described in detail below.
[0024] (Blood preservation composition) The blood storage composition of the present invention comprises an anticoagulant (A), a compound (B) which is a disaccharide, a disaccharide derivative, a polysaccharide or a polysaccharide derivative, and a polyether compound (C) which is polyethylene oxide or polyethylene glycol.
[0025] Since the blood storage composition of the present invention has the above-mentioned configuration, it is possible to prevent the intrusion of DNA derived from blood cells into the plasma layer, and to prevent a decrease in the plasma volume after storage compared to the plasma volume before storage.
[0026] The blood storage composition according to the present invention is mixed with blood before use. In the blood storage composition according to the present invention, compound (B) and polyether compound (C) effectively protect the cell membrane of blood cells, thereby enhancing the stability of blood cells. Therefore, leakage of blood cell-derived DNA outside the cells can be suppressed. In the present invention, for example, even if the blood storage composition and blood are mixed and stored at room temperature (4°C to 40°C) for about one week, the amount of blood cell-derived DNA mixed into plasma can be suppressed to a low level.
[0027] Furthermore, in the present invention, even if the blood is stored for about one week at room temperature (4°C to 40°C) after separation of the blood cell layer and the plasma layer, water in the plasma is less likely to be absorbed by the blood cells. Therefore, the decrease in the amount of plasma after storage can be suppressed compared to the amount of plasma before storage (the amount of plasma immediately after separation into the blood cell layer and the plasma layer).
[0028] The blood storage composition according to the present invention will be described in detail below. In this specification, the content of each component contained in the blood storage composition means the total content of all the components contained in the blood storage composition. For example, the content of anticoagulant (A) means the total content of all the anticoagulants (A) in the blood storage composition.
[0029] <Anticoagulant (A)> The blood storage composition contains an anticoagulant (sometimes referred to as anticoagulant (A) in this specification). As the anticoagulant (A), a conventionally known anticoagulant can be used. Only one type of anticoagulant (A) may be used, or two or more types may be used in combination.
[0030] Examples of the anticoagulant (A) include ethylenediaminetetraacetic acid (EDTA), metal salts of EDTA, heparin, metal salts of heparin, citric acid, and sodium citrate.
[0031] From the viewpoint of exerting good anticoagulant performance, the anticoagulant (A) is preferably EDTA, a metal salt of EDTA, heparin, a metal salt of heparin, or sodium citrate.
[0032] The content of the anticoagulant (A) in the blood storage composition is not particularly limited as long as it can exert anticoagulant properties.
[0033] When the blood storage composition contains water, the content of the anticoagulant (A) in 100% by weight of the blood storage composition is preferably 0.01% by weight or more, more preferably 0.1% by weight or more, preferably 5.0% by weight or less, more preferably 2.5% by weight or less. When the content of the anticoagulant (A) is equal to or more than the lower limit and equal to or less than the upper limit, the anticoagulant performance can be satisfactorily exhibited.
[0034] When the blood storage composition is substantially free of water, the content of the anticoagulant (A) in 100% by weight of the blood storage composition is preferably 0.5% by weight or more, more preferably 1% by weight or more, preferably 15% by weight or less, more preferably 10% by weight or less. When the content of the anticoagulant (A) is equal to or more than the lower limit and equal to or less than the upper limit, the anticoagulant performance can be satisfactorily exhibited.
[0035] <Disaccharides, disaccharide derivatives, polysaccharides, and compounds which are polysaccharide derivatives (B)> The blood storage composition contains a compound which is a disaccharide, a disaccharide derivative, a polysaccharide, or a polysaccharide derivative (sometimes referred to as compound (B) in this specification). Compound (B) is at least one compound selected from the group consisting of disaccharides, disaccharide derivatives, polysaccharides, and polysaccharide derivatives. Only one type of compound (B) may be used, or two or more types may be used in combination.
[0036] The compound (B) is preferably a water-soluble compound. The term "water-soluble" in the context of the compound (B) means that 0.5 g or more of the compound dissolves in 100 g of water at 25°C.
[0037] Examples of the disaccharides include sucrose, lactose, maltose, lactitol, trehalose, etc. The disaccharides may be used alone or in combination of two or more.
[0038] Examples of the disaccharide derivatives include trehalose 6-phosphate, etc. The disaccharide derivatives may be used alone or in combination of two or more.
[0039] Examples of the polysaccharides include cellulose, dextran, etc. The polysaccharides may be used alone or in combination of two or more kinds.
[0040] Examples of the polysaccharide derivatives include hydroxyethyl starch, hydroxypropyl cellulose, etc. The polysaccharide derivatives may be used alone or in combination of two or more.
[0041] The number average molecular weight of the polysaccharide or the derivative of the polysaccharide is preferably at least 1000, more preferably at least 10,000, even more preferably at least 100,000, and preferably at most 4 million, more preferably at most 1 million. When the number average molecular weight is at least the lower limit and at most the upper limit, the effects of the present invention can be more effectively exhibited.
[0042] The number average molecular weight means a number average molecular weight calculated as pullulan, measured by gel permeation chromatography (GPC).
[0043] Compound (B) is preferably a compound which is a disaccharide, a polysaccharide or a derivative of a polysaccharide, and more preferably a compound which is a disaccharide or a polysaccharide.
[0044] From the viewpoint of exerting the effect of the present invention more effectively, the compound (B) preferably contains a disaccharide and a polysaccharide or a derivative of a polysaccharide, and more preferably contains a disaccharide and a polysaccharide. The blood storage composition preferably contains a disaccharide and a polysaccharide or a derivative of a polysaccharide, and more preferably contains a disaccharide and a polysaccharide.
[0045] From the viewpoint of exerting the effect of the present invention more effectively, the disaccharide is preferably trehalose or sucrose, more preferably trehalose. The polysaccharide is preferably dextran. The derivative of the polysaccharide is preferably hydroxyethyl starch or hydroxypropyl cellulose, more preferably hydroxyethyl starch. From the viewpoint of exerting the effect of the present invention more effectively, the compound (B) preferably contains trehalose or sucrose, and dextran or hydroxyethyl starch, more preferably contains trehalose or sucrose and dextran, and even more preferably contains trehalose and dextran. From the viewpoint of exerting the effect of the present invention more effectively, the blood storage composition preferably contains trehalose or sucrose, and dextran or hydroxyethyl starch, more preferably contains trehalose or sucrose and dextran, and even more preferably contains trehalose and dextran.
[0046] In 100% by weight of compound (B), the content of the disaccharide is preferably 10% by weight or more, more preferably 20% by weight or more, preferably 80% by weight or less, more preferably 60% by weight or less. When the content of the disaccharide is equal to or more than the lower limit and equal to or less than the upper limit, the effects of the present invention can be more effectively exhibited.
[0047] In 100% by weight of the compound (B), the content of the polysaccharide is preferably 10% by weight or more, more preferably 30% by weight or more, preferably 90% by weight or less, more preferably 70% by weight or less. When the content of the polysaccharide is equal to or more than the lower limit and equal to or less than the upper limit, the effects of the present invention can be more effectively exhibited.
[0048] In 100% by weight of compound (B), the content of the polysaccharide derivative is preferably 10% by weight or more, more preferably 30% by weight or more, and preferably 90% by weight or less, more preferably 70% by weight or less. When the content of the polysaccharide derivative is equal to or more than the above lower limit and equal to or less than the above upper limit, the effects of the present invention can be more effectively exhibited.
[0049] When the blood storage composition is substantially free of water, the content of compound (B) in 100% by weight of the blood storage composition is preferably 10% by weight or more, more preferably 20% by weight or more, preferably 80% by weight or less, more preferably 70% by weight or less, even more preferably 60% by weight or less, and particularly preferably 50% by weight or less. When the content of compound (B) is equal to or more than the lower limit and equal to or less than the upper limit, the effects of the present invention can be more effectively exhibited.
[0050] When the blood storage composition contains water, the content of compound (B) in 100% by weight of the blood storage composition is preferably 0.1% by weight or more, more preferably 1% by weight or more, even more preferably 3% by weight or more, preferably 40% by weight or less, more preferably 30% by weight or less, and even more preferably 20% by weight or less. When the content of compound (B) is equal to or more than the lower limit and equal to or less than the upper limit, the effects of the present invention can be more effectively exhibited.
[0051] <Polyether compound (C) which is polyethylene oxide or polyethylene glycol> The blood storage composition contains a polyether compound (sometimes referred to as polyether compound (C) in this specification) which is polyethylene oxide or polyethylene glycol. The polyether compound (C) may be polyethylene oxide, polyethylene glycol, or both polyethylene oxide and polyethylene glycol. Only one type of polyether compound (C) may be used, or two or more types may be used in combination.
[0052] The polyether compound (C) is preferably a water-soluble polyether compound. The term "water-soluble" in the polyether compound (C) means that 0.5 g or more of the compound dissolves in 100 g of water at 25°C.
[0053] The number average molecular weight of the polyethylene oxide is preferably at least 600, more preferably at least 1000, even more preferably at least 2000, and preferably at most 20000, more preferably at most 8000. When the number average molecular weight is at least the above lower limit and at most the above upper limit, the effects of the present invention can be more effectively exhibited.
[0054] The number average molecular weight of the polyethylene glycol is preferably at least 500, more preferably at least 1000, even more preferably at least 2000, particularly preferably at least 3000, and preferably at most 25000, more preferably at most 10000, even more preferably at most 6000. When the number average molecular weight is at least the above lower limit and at most the above upper limit, the effects of the present invention can be exhibited even more effectively.
[0055] The number average molecular weight means a number average molecular weight calculated as pullulan, measured by gel permeation chromatography (GPC).
[0056] From the viewpoint of exerting the effect of the present invention more effectively, the polyether compound (C) preferably contains polyethylene glycol, more preferably is polyethylene glycol. The blood storage composition preferably contains polyethylene glycol.
[0057] The weight ratio of the content of polyether compound (C) to the content of compound (B) (content of polyether compound (C) / content of compound (B)) is preferably 0.01 or more, more preferably 0.1 or more, and preferably 5 or less, more preferably 1 or less. When the weight ratio (content of polyether compound (C) / content of compound (B)) is equal to or more than the above lower limit and equal to or less than the above upper limit, the effects of the present invention can be more effectively exhibited.
[0058] When the blood storage composition is substantially free of water, the content of the polyether compound (C) in the blood storage composition (100% by weight) is preferably 5.0% by weight or more, more preferably 10% by weight or more, even more preferably 20% by weight or more, preferably 80% by weight or less, more preferably 70% by weight or less, even more preferably 60% by weight or less, and particularly preferably 50% by weight or less. When the content of the polyether compound (C) is equal to or more than the lower limit and equal to or less than the upper limit, the effects of the present invention can be more effectively exhibited.
[0059] When the blood storage composition contains water, the content of the polyether compound (C) in 100% by weight of the blood storage composition is preferably 0.1% by weight or more, more preferably 1.0% by weight or more, even more preferably 5.0% by weight or more, preferably 40% by weight or less, more preferably 20% by weight or less, and even more preferably 15% by weight or less. When the content of the polyether compound (C) is equal to or more than the lower limit and equal to or less than the upper limit, the effects of the present invention can be more effectively exhibited.
[0060] <Apoptosis inhibitors (D)> The blood storage composition preferably contains an apoptosis inhibitor (sometimes referred to as apoptosis inhibitor (D) in this specification). By using the apoptosis inhibitor (D), cell death of blood cells during storage can be effectively suppressed, and leakage of blood cell-derived DNA outside the cells can be more effectively suppressed. Only one type of apoptosis inhibitor (D) may be used, or two or more types may be used in combination.
[0061] Examples of the apoptosis inhibitor (D) include Q-VD-OPH, Z-DEVD-FMK, and Z-VAD-FMK.
[0062] From the viewpoint of exerting the effect of the present invention more effectively, the apoptosis inhibitor (D) is preferably a caspase inhibitor, more preferably contains Q-VD-OPH, Z-DEVD-FMK, or Z-VAD-FMK, even more preferably contains Q-VD-OPH, and particularly preferably is Q-VD-OPH. The blood storage composition preferably contains Q-VD-OPH, Z-DEVD-FMK, or Z-VAD-FMK, and more preferably contains Q-VD-OPH.
[0063] The weight ratio of the content of the apoptosis inhibitor (D) to the content of the compound (B) (content of the apoptosis inhibitor (D) / content of the compound (B)) is preferably 0.0001 or more, more preferably 0.0005 or more, preferably 0.1 or less, more preferably 0.01 or less. When the weight ratio (content of the apoptosis inhibitor (D) / content of the compound (B)) is equal to or more than the lower limit and equal to or less than the upper limit, the incorporation of DNA derived from blood cells into the plasma layer can be further suppressed.
[0064] When the blood storage composition is substantially free of water, the content of the apoptosis inhibitor (D) in the blood storage composition (100% by weight) is preferably 0.001% by weight or more, more preferably 0.005% by weight or more, preferably 1.0% by weight or less, more preferably 0.1% by weight or less. When the content of the apoptosis inhibitor (D) is equal to or more than the lower limit and equal to or less than the upper limit, the incorporation of DNA derived from blood cells into the plasma layer can be further suppressed.
[0065] When the blood storage composition contains water, the content of the apoptosis inhibitor (D) in the blood storage composition (100% by weight) is preferably 0.0001% by weight or more, more preferably 0.001% by weight or more, even more preferably 0.005% by weight or more, preferably 0.1% by weight or less, more preferably 0.01% by weight or less. When the content of the apoptosis inhibitor (D) is equal to or more than the lower limit and equal to or less than the upper limit, the incorporation of DNA derived from blood cells into the plasma layer can be further suppressed.
[0066] <Inorganic salts (E)> The blood storage composition preferably contains an inorganic salt (sometimes referred to as inorganic salt (E) in this specification). By using the inorganic salt (E), the osmotic pressure of the mixture of the blood storage composition and blood can be adjusted to a suitable range, effectively suppressing cell death of blood cells during storage. This makes it possible to further suppress contamination of the plasma layer with DNA derived from blood cells. Only one type of inorganic salt (E) may be used, or two or more types may be used in combination.
[0067] Examples of the inorganic salt (E) include sodium chloride, calcium chloride, potassium chloride, magnesium chloride, phosphates, carbonates, and borates. Examples of the phosphates include sodium phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, trisodium phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, and dipotassium phosphate. Examples of the carbonates include sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, and ammonium carbonate. Examples of the borates include sodium borate.
[0068] The weight ratio of the content of inorganic salt (E) to the content of compound (B) (content of inorganic salt (E) / content of compound (B)) is preferably 0.01 or more, more preferably 0.1 or more, and preferably 10 or less, more preferably 5 or less. When the weight ratio (content of inorganic salt (E) / content of compound (B)) is equal to or more than the above lower limit and equal to or less than the above upper limit, the incorporation of blood cell-derived DNA into the plasma layer can be further suppressed.
[0069] When the blood storage composition is substantially free of water, the content of the inorganic salt (E) in the blood storage composition (100% by weight) is preferably 0.5% by weight or more, more preferably 5.0% by weight or more, preferably 40% by weight or less, more preferably 20% by weight or less. When the content of the inorganic salt (E) is equal to or more than the lower limit and equal to or less than the upper limit, the incorporation of DNA derived from blood cells into the plasma layer can be further suppressed.
[0070] When the blood storage composition contains water, the content of the inorganic salt (E) in 100% by weight of the blood storage composition is preferably 0.1% by weight or more, more preferably 1.0% by weight or more, preferably 10% by weight or less, more preferably 5.0% by weight or less. When the content of the inorganic salt (E) is equal to or more than the lower limit and equal to or less than the upper limit, the incorporation of DNA derived from blood cells into the plasma layer can be further suppressed.
[0071] <Water> The blood storage composition does not contain water or contains water. The blood storage composition may contain water or may not substantially contain water. "Substantially water-free" means that water is not intentionally added, and for example, the amount of water contained in the raw material (for example, water present as a hydrate or water present as an impurity) or water mixed from the air is within an acceptable range. Specifically, "the blood storage composition does not substantially contain water" means that the water content is 0% by weight or more and 5% by weight or less, preferably 3% by weight or less, more preferably 1% by weight or less, in 100% by weight of the blood storage composition. When the blood storage composition contains water, for example, the blood storage composition can be contained in the blood collection container body in a liquid state. When the blood storage composition does not substantially contain water, for example, the blood storage composition can be contained in the blood collection container body in a powder state.
[0072] When the blood storage composition contains water, the water content in 100% by weight of the blood storage composition is preferably 50% by weight or more, more preferably 70% by weight or more, preferably 95% by weight or less, more preferably 90% by weight or less.
[0073] <Other ingredients> The above-mentioned blood storage composition may contain components other than those mentioned above (anticoagulant (A), compound (B), polyether compound (C), apoptosis inhibitor (D), inorganic salt (E) and water).
[0074] Examples of the other components include monosaccharides, amino acids, necroptosis inhibitors, antioxidants, and metabolic inhibitors. The other components may be used alone or in combination of two or more.
[0075] <Other details of blood storage composition> The blood storage composition may be in a liquid or powder form at 25° C. The blood storage composition may be in a dry form or a lyophilized form.
[0076] When the blood storage composition is substantially free of water, the total content of the anticoagulant (A), the compound (B) and the polyether compound (C) in the blood storage composition (100% by weight) is preferably 10% by weight or more, more preferably 30% by weight or more, even more preferably 50% by weight or more, particularly preferably 70% by weight or more, preferably 98% by weight or less, more preferably 95% by weight or less. When the total content is equal to or more than the lower limit and equal to or less than the upper limit, the effects of the present invention can be more effectively exhibited.
[0077] When the blood storage composition does not substantially contain water, the total content of the anticoagulant (A), the compound (B), the polyether compound (C) and the inorganic salt (E) in 100% by weight of the blood storage composition is preferably 50% by weight or more, more preferably 75% by weight or more, even more preferably 80% by weight or more, even more preferably 90% by weight or more, and particularly preferably 95% by weight or more. When the total content is equal to or more than the lower limit, the effect of the present invention can be more effectively exhibited. When the blood storage composition does not substantially contain water, the total content of the anticoagulant (A), the compound (B), the polyether compound (C) and the inorganic salt (E) in 100% by weight of the blood storage composition is 100% by weight or less, may be less than 100% by weight, may be 99% by weight or less, may be 95% by weight or less, or may be 90% by weight or less.
[0078] When the blood storage composition contains water, the total content of the anticoagulant (A), the compound (B), the polyether compound (C) and water in the blood storage composition (100% by weight) is preferably 10% by weight or more, more preferably 30% by weight or more, even more preferably 50% by weight or more, particularly preferably 70% by weight or more, preferably 98% by weight or less, more preferably 95% by weight or less. When the total content is equal to or more than the lower limit and equal to or less than the upper limit, the effects of the present invention can be more effectively exhibited.
[0079] When the blood storage composition contains water, the total content of the anticoagulant (A), the compound (B), the polyether compound (C), the inorganic salt (E) and water in 100% by weight of the blood storage composition is preferably 50% by weight or more, more preferably 75% by weight or more, even more preferably 80% by weight or more, even more preferably 90% by weight or more, and particularly preferably 95% by weight or more. When the total content is equal to or more than the lower limit, the effect of the present invention can be more effectively exhibited. When the blood storage composition contains water, the total content of the anticoagulant (A), the compound (B), the polyether compound (C), the inorganic salt (E) and water in 100% by weight of the blood storage composition is 100% by weight or less, may be less than 100% by weight, may be 99% by weight or less, may be 95% by weight or less, or may be 90% by weight or less.
[0080] (Blood collection container) The blood collection container of the present invention comprises a blood collection container body and a blood storage composition contained within the blood collection container body, and the blood storage composition is the blood storage composition described above.
[0081] FIG. 1 is a front cross-sectional view that shows a schematic diagram of a blood collection container according to one embodiment of the present invention.
[0082] The blood collection container 5 shown in FIG. 1 comprises a blood collection container body 1, a blood storage composition 2, and a stopper 3. The blood collection container body 1 has an opening at one end and a bottom portion that is closed at the other end. The blood storage composition 2 is contained in the bottom portion of the blood collection container body 1 when the blood collection container 5 is in an upright position. The blood storage composition 2 contains an anticoagulant (A), a compound (B), and a polyether compound (C). The stopper 3 is inserted into the opening of the blood collection container body 1.
[0083] <Blood collection container body> The shape of the blood collection container body is not particularly limited. The blood collection container body is preferably a tubular container with a bottom.
[0084] The material of the blood collection container body is not particularly limited. Examples of the material of the blood collection container body include thermoplastic resins such as polyethylene, polypropylene, polystyrene, polyethylene terephthalate, polymethyl methacrylate, and polyacrylonitrile; thermosetting resins such as unsaturated polyester resins, epoxy resins, and epoxy-acrylate resins; modified natural resins such as cellulose acetate, cellulose propionate, ethyl cellulose, and ethyl chitin; and glass such as silicate glass such as soda-lime glass, phosphosilicate glass, and borosilicate glass, and quartz glass. Only one type of material may be used for the blood collection container body, or two or more types may be used in combination.
[0085] <Bung body> The blood collection container preferably includes a stopper. The stopper is preferably attached to the opening of the blood collection container body. A conventionally known stopper can be used as the stopper. The stopper is preferably made of a material and has a shape that allows it to be attached to the opening of the blood collection container body in an airtight and liquidtight manner. The stopper is preferably configured to be pierced by a blood collection needle.
[0086] Examples of the stopper include a stopper having a shape that fits into the opening of the blood collection container body, a sheet-like seal stopper, and the like.
[0087] The stopper may include a stopper body such as a rubber stopper and a cap member made of plastic, etc. In this case, the risk of blood coming into contact with the human body can be reduced when the stopper body is pulled out from the opening of the blood collection container body after blood collection.
[0088] Examples of the material of the stopper (or the stopper main body) include synthetic resin, elastomer, rubber, metal foil, etc. Examples of the rubber include butyl rubber and halogenated butyl rubber, etc. Examples of the metal foil include aluminum foil, etc. From the viewpoint of improving the sealing performance, the material of the stopper is preferably butyl rubber. The stopper (or the stopper main body) is preferably a butyl rubber stopper.
[0089] <Other details of blood collection container> The blood collection container is a blood collection container in which a predetermined amount of blood is collected. The predetermined amount of blood is appropriately changed depending on the size and internal pressure of the blood collection container. The predetermined amount of blood may be 1 mL or more, 2 mL or more, 4 mL or more, 12 mL or less, 11 mL or less, or 10 mL or less.
[0090] A physiological saline solution in an amount equal to a predetermined amount of blood collected in the blood collection container is collected in the blood collection container, and a mixed solution in which the physiological saline solution and the blood preservation composition are mixed is obtained. For example, in a blood collection container in which 5 mL of blood is collected, 5 mL of physiological saline solution is collected in the blood collection container, and the physiological saline solution and the blood preservation composition are mixed by inversion or the like to obtain a mixed solution. The osmotic pressure of the mixed solution in which the physiological saline solution and the blood preservation composition are mixed is preferably 300 mOsm / L or more, more preferably 330 mOsm / L or more, even more preferably 350 mOsm / L or more, preferably 3000 mOsm / L or less, more preferably 2000 mOsm / L or less, and even more preferably 1500 mOsm / L or less. When the osmotic pressure of the mixed solution is above the lower limit and below the upper limit, excessive stress on white blood cells is suppressed, and white blood cells can be further stabilized, so that the effect of the present invention can be exerted more effectively.
[0091] The osmotic pressure of the above-mentioned mixed solution is measured by the freezing point depression method using an osmometer (for example, "OM-6060" manufactured by Arkray, Inc.).
[0092] The amount of the blood preservation composition contained in the blood collection container body is appropriately changed depending on the size of the blood collection container body, the amount of blood to be collected, etc. When the blood preservation composition is liquid at 25°C, the amount of the blood preservation composition contained in the blood collection container body is preferably 0.1 mL or more, more preferably 0.5 mL or more, even more preferably 0.7 mL or more, preferably 5 mL or less, more preferably 3 mL or less, and even more preferably 2.5 mL or less. When the amount of the blood preservation composition is above the lower limit and below the upper limit, the blood is not excessively diluted, and the effects of the present invention can be more effectively exhibited.
[0093] When the blood storage composition is liquid at 25° C., the blood is preferably collected in an amount of 3 mL or more, more preferably 4 mL or more, more preferably 11 mL or less, and even more preferably 10 mL or less per mL of the blood storage composition contained in the blood collection container. In this case, the blood is not excessively diluted, and the effects of the present invention can be more effectively achieved.
[0094] In the blood collection container, it is preferable that the blood collection container body does not contain a plasma separation material. The plasma separation material is a composition (plasma separation composition) or a tool (plasma separation tool) that moves between the plasma layer and the blood cell layer during centrifugation to form a partition. The plasma separation composition includes a composition containing an organic component having fluidity at 25°C and an inorganic fine powder (for example, the composition described in WO2010 / 053180A1). The plasma separation tool includes, for example, a mechanical separator described in WO2010 / 132783A1. In the blood collection container containing the blood storage composition, the reduction in the amount of plasma after storage can be suppressed compared to the amount of plasma before storage, so a plasma separation material may not be provided.
[0095] The blood collection container is preferably a blood collection tube. The blood collection container body is preferably a blood collection tube body.
[0096] The blood collection container can be manufactured, for example, as follows.
[0097] The anticoagulant (A), the compound (B), the polyether compound (C), and optionally other components are mixed to obtain a blood storage composition, which is then placed in the blood collection container body.
[0098] The internal pressure of the blood collection container is not particularly limited. The internal pressure of the blood collection container is preferably reduced. When the blood collection container is a reduced pressure container, a predetermined amount of blood can be easily collected in the blood collection container. The blood collection container can also be used as a vacuum blood collection tube, the inside of which is evacuated and sealed with the stopper. When it is a vacuum blood collection tube, a constant amount of blood can be easily collected regardless of the skill level of the blood collector.
[0099] From the viewpoint of preventing bacterial infection, the inside of the blood collection container is preferably sterilized in accordance with ISO or JIS standards.
[0100] (Plasma Separation Method) The blood collection container can be used to separate plasma from blood. The method for separating plasma preferably includes a step of collecting blood in the blood collection container, and a step of centrifuging the blood collection container in which the blood has been collected.
[0101] In the plasma separation method, it is preferable to include a step of mixing the collected blood with the blood preservation composition between the step of collecting the blood and the step of centrifuging the blood. Examples of a method for mixing the collected blood with the blood preservation composition include mixing by inversion.
[0102] The centrifugation conditions in the centrifugation step are not particularly limited, and examples of the centrifugation conditions include centrifugation at 400 G or more and 4000 G or less for 10 minutes or more and 120 minutes or less.
[0103] (Method for isolating extracellular free nucleic acids and method for isolating extracellular vesicles) The blood collection container can be used to separate extracellular free nucleic acid from blood. The method for separating extracellular free nucleic acid preferably includes a step of collecting blood in the blood collection container, a step of centrifuging the blood collection container into which the blood has been collected to separate plasma from the blood, and a step of separating extracellular free nucleic acid from the separated plasma.
[0104] The blood collection container can be used to separate extracellular vesicles from blood. The method for separating extracellular vesicles preferably includes a step of collecting blood in the blood collection container, a step of separating plasma from the blood by centrifuging the blood collection container in which the blood has been collected, and a step of separating extracellular vesicles from the separated plasma.
[0105] In the method for isolating extracellular free nucleic acids and the method for isolating extracellular vesicles, it is preferable to include a step of mixing the collected blood with the blood preservation composition between the step of collecting the blood and the step of centrifuging. Examples of a method for mixing the collected blood with the blood preservation composition include mixing by inversion.
[0106] The centrifugation conditions in the centrifugation step are not particularly limited, and examples of the centrifugation conditions include centrifugation at 400 G or more and 4000 G or less for 10 minutes or more and 120 minutes or less.
[0107] In the step of separating the extracellular free nucleic acid, the extracellular free nucleic acid can be separated from the plasma using a conventionally known method. The extracellular free nucleic acid includes cell free DNA (cfDNA) and cell free RNA (cfRNA). The method of separating the extracellular free nucleic acid from the plasma includes a method using a commercially available nucleic acid purification kit. By using a commercially available nucleic acid purification kit, the extracellular free nucleic acid can be easily separated from the plasma. Examples of the commercially available nucleic acid purification kit include QIAamp Circulating Nucleic Acid Kit (QIAGEN), QIAamp MinElute ccfDNA Kits (QIAGEN), and MagMAX Cell-Free DNA Isolation Kit (Applied biosystems).
[0108] In the step of separating extracellular vesicles, extracellular vesicles can be separated from plasma using a conventionally known method.
[0109] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to the following examples.
[0110] The following materials were prepared as blood storage composition materials.
[0111] (Anticoagulant (A)) Dipotassium ethylenediaminetetraacetate dihydrate (EDTA2K 2H2O)
[0112] (Compound (B)) Trehalose sucrose Dextran (number average molecular weight: 37500, Fujifilm Wako Pure Chemical Industries, Ltd. "Dextran 40000") Hydroxyethyl starch (number average molecular weight: approximately 20,000, "Hydroxyethyl starch" manufactured by Santa Cruz Biotechnology Inc.)
[0113] (Polyether Compound (C)) Polyethylene glycol (1) (number average molecular weight: 3000, Fujifilm Wako Pure Chemical Industries, Ltd. "Polyethylene glycol 4,000") Polyethylene glycol (2) (number average molecular weight: 600, Fujifilm Wako Pure Chemical Industries, Ltd. "Polyethylene glycol 600") Polyethylene glycol (3) (number average molecular weight: 20,000, Fujifilm Wako Pure Chemical Industries, Ltd. "Polyethylene glycol 20,000")
[0114] (Apoptosis inhibitors (D)) Q-VD-OPH (Q-VD-OPH manufactured by Cayman Chemical Co.) Z-DEVD-FMK (Cosmobio "Z-DEVD-FMK") Z-VAD-FMK (Cosmobio "Z-VAD-FMK")
[0115] (Inorganic Salts (E)) Sodium chloride
[0116] water
[0117] Example 1 Preparation of blood storage composition: The components were mixed in the proportions shown in Table 1 to prepare a blood storage composition (aqueous solution).
[0118] Preparation of blood collection containers: A polyethylene terephthalate bottomed tube (PET bottomed tube) with a length of 100 mm and an inner diameter of the opening of 14 mm was prepared as the blood collection container body. 1.0 mL of the obtained blood storage composition was placed in the PET bottomed tube. Next, the inside of the blood collection container was depressurized to 50 kPa and sealed with a butyl rubber stopper. In this way, a blood collection container for collecting and storing 5.0 mL of blood was prepared.
[0119] (Example 2 5, Reference Examples 6 and 7, and Example 8 10 and Comparative Examples 1 and 2) A blood storage composition and a blood collection container were prepared in the same manner as in Example 1, except that the blending composition of the blood storage composition was changed as shown in Tables 1 to 3.
[0120] Comparative Example 3 An anticoagulant-containing solution was obtained by dissolving 33 parts by weight of anticoagulant (EDTA2K·2H2O) in 67 parts by weight of water. In addition, a polyethylene terephthalate bottomed tube (PET bottomed tube) with a length of 100 mm and an inner diameter of the opening of 14 mm was prepared as the blood collection container body. 26 mg of the obtained anticoagulant-containing solution was applied to the inner wall surface of the blood collection container body and dried. Next, the inside of the blood collection container was depressurized so that the blood collection volume was 5.0 mL, and the container was sealed with a butyl rubber stopper. In this manner, the blood collection container was produced.
[0121] (evaluation) (1) Contamination of the plasma layer with DNA from blood cells (DNA concentration in plasma) Example 1 5, Reference Examples 6 and 7, and Example 8In Comparative Examples 10 and 1 and 2, 5.0 mL of blood was collected in the obtained blood collection container, and the blood and the blood storage composition (aqueous solution) were mixed by inversion mixing. In Comparative Example 3, 5.0 mL of blood was collected in the obtained blood collection container, and the blood and the EDTA2K attached to the inner wall surface of the blood collection container body were mixed by inversion mixing. Then, the blood collection container containing the mixed solution was stored in an environment of 25°C. After 8 days of storage, the blood collection container containing the mixed solution was centrifuged at 1900G for 15 minutes to separate it into a plasma layer (upper) and a blood cell layer (lower). Then, the plasma was collected from the blood collection container. The DNA contained in the collected plasma was purified using a cfDNA purification kit (QIAamp Circulating Nucleic Acid Kit manufactured by QIAGEN). The DNA purification operation was performed on the day the plasma was collected from the blood collection container.
[0122] The DNA concentration in the purified extract was measured using a Qubit dsDNA HS Assay kit (Invitrogen). The DNA concentration (the amount of DNA contained per mL of plasma) was then calculated using the following formula.
[0123] DNA concentration (ng / 1mL plasma)=[A]×[B] / [C]
[0124] [A]: Measured DNA concentration in the purified extract (ng / mL) [B]: Total volume of purified extract (mL) [C]: Volume of plasma used for DNA purification (mL)
[0125] The DNA concentration (ng / mL of plasma) calculated in Comparative Example 3 was compared with that in Examples 1 to 5, Reference Examples 6 and 7, and Example 8 The ratios (relative ratios to Comparative Example 3) of the above DNA concentrations (ng / mL of plasma) calculated in Comparative Examples 10 and 1 and 2 were calculated using the following formula.
[0126] Relative ratio to Comparative Example 3 (%)=[P] / [Q]×100
[0127] [P]: Example 1 5, Reference Examples 6 and 7, and Example 8DNA concentration calculated in 10 and Comparative Examples 1 and 2 (ng / mL of plasma) [Q]: DNA concentration calculated in Comparative Example 3 (ng / mL of plasma)
[0128] The smaller the relative ratio, the more suppressed the leakage of DNA derived from blood cells (leakage of genomic DNA outside the cells). The results in the table are the average values when the blood of two people was tested.
[0129] (2) Change in plasma volume before and after storage Example 1 5, Reference Examples 6 and 7, and Example 8 In Comparative Example 10 and Comparative Examples 1 and 2, 5.0 mL of blood was collected in the obtained blood collection container, and the blood and the blood preservation composition (aqueous solution) were mixed by inversion mixing. In Comparative Example 3, 5.0 mL of blood was collected in the obtained blood collection container, and the blood and the EDTA2K attached to the inner wall surface of the blood collection container body were mixed by inversion mixing. The blood collection container containing the mixed solution was centrifuged at 1900G for 15 minutes. After centrifugation, the length (height) of the plasma layer in the blood collection container was measured with a vernier caliper. Next, the blood cells and plasma were mixed by inversion mixing, and the blood collection container was stored for 7 days in an environment of 25°C. After storage for 7 days, the blood collection container was centrifuged at 1900G for 15 minutes. After centrifugation, the length (height) of the plasma layer in the blood collection container was measured with a vernier caliper. Next, the relative ratio of the plasma volume after storage to the plasma volume before storage was calculated using the following formula. The rate of change in plasma volume before and after storage was evaluated according to the following criteria: The length of the plasma layer is the average value when the blood of two subjects was tested.
[0130] Relative percentage of plasma volume after storage (%) = [X] / [Y] × 100
[0131] [X]: Length of plasma layer after 7 days of storage (mm) [Y]: Length of plasma layer before storage (mm)
[0132] <Criteria for determining the rate of change in plasma volume before and after storage> ○: The relative proportion of plasma volume after storage is 89% or more ×: The relative proportion of plasma volume after storage is less than 89%
[0133] The composition and results are shown in Tables 1 to 3 below. Note that in the tables, the concentration of the anticoagulant refers to the concentration of EDTA2K, not the concentration of EDTA2K·2H2O. The contents of other components are pure amounts.
[0134] [Table 1]
[0135] [Table 2]
[0136] [Table 3] [Explanation of symbols]
[0137] 1…Blood collection container body 2...Blood preservation composition 3…Bung body 5. Blood collection container
Claims
1. An anticoagulant (A); A compound (B) which is a disaccharide, a disaccharide derivative, a polysaccharide, or a polysaccharide derivative; and a polyether compound (C) which is polyethylene oxide or polyethylene glycol; The compound (B) comprises a disaccharide and a polysaccharide or a derivative of a polysaccharide, A blood storage composition, wherein the weight ratio of the content of the polyether compound (C) to the content of the compound (B) is 0.01 or more and 5 or less.
2. A blood storage composition as described in claim 1, wherein the content of the disaccharide in 100% by weight of the compound (B) is 10% by weight or more and 80% by weight or less.
3. The compound (B) comprises the polysaccharide, 3. The blood storage composition according to claim 1, wherein the content of the polysaccharide is 10% by weight or more and 90% by weight or less in 100% by weight of the compound (B).
4. The compound (B) comprises a derivative of the polysaccharide, 3. The blood storage composition according to claim 1, wherein the content of the polysaccharide derivative in 100% by weight of the compound (B) is 10% by weight or more and 90% by weight or less.
5. 3. The blood storage composition according to claim 1 or 2, wherein the compound (B) comprises trehalose or sucrose, and dextran or hydroxyethyl starch.
6. The blood storage composition according to claim 1 or 2, wherein the polyether compound (C) comprises polyethylene glycol.
7. A blood storage composition as described in claim 6, wherein the number average molecular weight of the polyethylene glycol is 500 or more and 25,000 or less.
8. The blood storage composition according to claim 1 or 2, comprising an apoptosis inhibitor (D).
9. The blood storage composition of claim 8, wherein the apoptosis inhibitor (D) comprises Q-VD-OPH, Z-DEVD-FMK, or Z-VAD-FMK.
10. The blood storage composition according to claim 1 or 2, which contains an inorganic salt (E).
11. A blood storage composition as described in claim 10, wherein the weight ratio of the content of the inorganic salt (E) to the content of the compound (B) is 0.01 or more and 10 or less.
12. The blood storage composition according to claim 1 or 2, which contains water.
13. A blood collection container body; A blood storage composition contained in the blood collection container body, A blood collection container, wherein the blood storage composition is the blood storage composition according to claim 1 or 2.
14. The blood collection container according to claim 13 , wherein the blood collection container body does not contain a plasma separator.
Citation Information
Patent Citations
Blood cfDNA extracting kit
CN109750087A
Whole blood free DNA preservative, vacuum blood collection tube and preparation method of vacuum blood collection tube
CN112359091A
Stabilization and isolation of extracellular nucleic acids
JP2014528719A
Stabilization and isolation of extracellular nucleic acids
JP2016518827A
Blood collection device for improved nucleic acid regulation
WO2013123030A2
